Neurocrine Biosciences Presents INGREZZA Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated with Huntington's disease Through Week 50 at Huntington Study Group 2023

SAN DIEGO - Neurocrine Biosciences, Inc. today announced interim results from the ongoing open-label KINECT-HD2 study about INGREZZA capsules when used for the long-term treatment of adults with...

Related Keywords

Phoenix ,Arizona ,United States ,Neurocrine Biosciences ,Aimee White ,Neurocrine Bioscience ,Eiryw Roberts ,Exchange Commission ,Huntington Disease Health Index ,Clinical Research Inc ,Drug Administration ,Nasdaq ,Huntington Study Group ,A Wearable Movement Sensor Substudy ,Neurocrine Biosciences Inc ,Annual Meeting ,Study Group ,Chief Medical Officer ,Chorea Associated With Huntington ,Interim Results From ,Long Term Open Label Study ,Wearable Movement Sensor Substudy ,Disease Health Index ,Measuring Changes ,Disease Burden ,Valbenazine During ,Minimal Clinically Important Difference ,Maximal Chorea Score ,Chorea Severity ,Treatment Comparison ,Valbenazine With Deutetrabenazine ,Total Maximal Chorea Score ,Chorea Associated ,Unified Huntington ,Disease Rating Scale ,Total Maximal Chorea ,Clinical Global Impression ,Patient Global Impression ,News Publishing ,Markets ,